Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mucormycosis in hematologic patients.

Livio Pagano1, Massimo Offidani, Luana Fianchi

  • 1Istituto di Ematologia, Università Cattolica S. Cuore, Roma, Italy. lpagano@rm.unicatt.it

Haematologica
|March 9, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.

Blood neoplasia·2026
Same author

Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols.

Bone marrow transplantation·2026
Same author

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same author

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Blood advances·2026
Same author

Key Indications for Passive Immune Prophylaxis Against SARS-CoV-2 Infection in Malignant Hematological Disorders: An Analytic Hierarchy Process by an Ad Hoc Italian Expert Panel.

Vaccines·2026
Same author

Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex-Stratified Analysis of the GIMEMA AML1310 Trial.

American journal of hematology·2026

Mucormycosis in hematologic malignancy patients is deadly, but liposomal amphotericin B treatment improves outcomes. Early diagnosis and aggressive treatment are crucial for survival in these high-risk fungal infections.

Area of Science:

  • Medical Mycology
  • Hematology
  • Infectious Diseases

Background:

  • Mucormycosis is a severe fungal infection.
  • It disproportionately affects patients with hematologic malignancies, particularly those who are neutropenic.

Purpose of the Study:

  • To analyze clinical features of mucormycosis in hematologic malignancy patients.
  • To identify factors influencing patient outcomes after fungal infection.

Main Methods:

  • Retrospective study over 15 years (1987-2001).
  • Inclusion of 59 patients with proven/probable mucormycosis and hematologic malignancies.
  • Analysis of antifungal treatments and surgical interventions.

Main Results:

  • Lung and orbito-sinus-facial regions were most frequently infected.

Related Experiment Videos

  • Mortality rate was high (63%), with mucormycosis being the primary cause of death.
  • Liposomal amphotericin B treatment was the only factor significantly correlating with recovery.

    • Conclusions:

    • Mucormycosis remains a significant threat in neutropenic patients with acute leukemia.
    • Despite recent improvements, mortality rates are still high.
    • Aggressive diagnostic and therapeutic strategies are vital to enhance patient prognosis.